Hybio Pharmaceutical (300199) - Total Liabilities
Based on the latest financial reports, Hybio Pharmaceutical (300199) has total liabilities worth CN¥2.50 Billion CNY (≈ $366.50 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 300199 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Hybio Pharmaceutical - Total Liabilities Trend (2007–2024)
This chart illustrates how Hybio Pharmaceutical's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Hybio Pharmaceutical assets under control.
Hybio Pharmaceutical Competitors by Total Liabilities
The table below lists competitors of Hybio Pharmaceutical ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PENNON GROUP PLC UNS.ADR2
F:3PN0
|
Germany | €6.02 Billion |
|
Changzhou Xingyu Automotive Lighting Systems Co Ltd
SHG:601799
|
China | CN¥7.53 Billion |
|
Shanghai Daimay Auto Interior
SHG:603730
|
China | CN¥2.57 Billion |
|
Robotis Co.Ltd
KQ:108490
|
Korea | ₩10.97 Billion |
|
Knowles Cor
NYSE:KN
|
USA | $280.50 Million |
|
XJ Electric Co Ltd
SHE:000400
|
China | CN¥12.28 Billion |
|
Veidekke ASA
OL:VEI
|
Norway | Nkr15.89 Billion |
|
Orion Oyj A
HE:ORNAV
|
Finland | €726.20 Million |
Liability Composition Analysis (2007–2024)
This chart breaks down Hybio Pharmaceutical's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Hybio Pharmaceutical (300199) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.86 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.79 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hybio Pharmaceutical's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hybio Pharmaceutical (2007–2024)
The table below shows the annual total liabilities of Hybio Pharmaceutical from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥2.41 Billion ≈ $352.83 Million |
-3.32% |
| 2023-12-31 | CN¥2.49 Billion ≈ $364.95 Million |
+7.76% |
| 2022-12-31 | CN¥2.31 Billion ≈ $338.65 Million |
+2.47% |
| 2021-12-31 | CN¥2.26 Billion ≈ $330.48 Million |
-3.59% |
| 2020-12-31 | CN¥2.34 Billion ≈ $342.77 Million |
-5.99% |
| 2019-12-31 | CN¥2.49 Billion ≈ $364.61 Million |
+9.83% |
| 2018-12-31 | CN¥2.27 Billion ≈ $331.97 Million |
+60.53% |
| 2017-12-31 | CN¥1.41 Billion ≈ $206.79 Million |
+65.78% |
| 2016-12-31 | CN¥852.42 Million ≈ $124.74 Million |
-6.19% |
| 2015-12-31 | CN¥908.68 Million ≈ $132.97 Million |
+126.43% |
| 2014-12-31 | CN¥401.32 Million ≈ $58.73 Million |
+144.00% |
| 2013-12-31 | CN¥164.48 Million ≈ $24.07 Million |
+53.11% |
| 2012-12-31 | CN¥107.42 Million ≈ $15.72 Million |
+80.36% |
| 2011-12-31 | CN¥59.56 Million ≈ $8.72 Million |
+84.40% |
| 2010-12-31 | CN¥32.30 Million ≈ $4.73 Million |
-40.99% |
| 2009-12-31 | CN¥54.73 Million ≈ $8.01 Million |
+46.64% |
| 2008-12-31 | CN¥37.32 Million ≈ $5.46 Million |
+291.21% |
| 2007-12-31 | CN¥9.54 Million ≈ $1.40 Million |
-- |
About Hybio Pharmaceutical
Hybio Pharmaceutical Co., Ltd. engages in the research, development, production, and marketing of peptide and oligonucleotide drugs in China and internationally. The company offers finished dosage form (FDF) products for obstetrics and gynecology, haemostatic agent, digestive tract and metabolic systems, immune system modulation, cardiovascular, diabetes mellitus, and osteoporosis, as well as dis… Read more